Pharmacokinetics of Subcutaneous versus Intramuscular Administration of Ceftiofur Crystalline-Free Acid in Inland Bearded Dragons (Pogona vitticeps)
American Association of Zoo Veterinarians Conference 2013
Sarah M. Churgin1, DVM; Kari Musgrave1, BA; Sherry Cox2, PhD; Kurt Sladky1, DVM, DACZM
1Department of Surgical Sciences, Special Species Health Service, University of Wisconsin, Madison, WI, USA; 2Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, USA

Abstract

The objective of this study was to evaluate the pharmacokinetics of ceftiofur crystalline-free acid (CCFA),a the long-acting formulation of ceftiofur, after subcutaneous (SC) and intramuscular (IM) administration in bearded dragons (Pogona vitticeps, n=6). Ceftiofur is a third-generation cephalosporin with broad-spectrum bactericidal activity.2 A recent study of CCFA in ball pythons (Python regius) yielded promising results, but concluded that a higher dosage than was tested (15 mg/kg IM) might be more effective.1 In the current study, each bearded dragon received a single dose of 30 mg/kg CCFA IM or SC; the experiment was then repeated after a 28-day wash-out period using the opposite route of administration for each animal in a complete crossover design. Blood samples were collected from each animal during each phase of the experiment at the following times: 0, 4, 12, 24, 48, 72, 120, 144, 192, and 288 h post-injection. A target minimum-inhibitory concentration (MIC) of 1 μg/mL was selected based on previous MIC research of common bacterial isolates in turkey poults.3 Results indicate that both routes of administration achieved plasma levels of ceftiofur equivalents above 1 μg/mL by 4 h post-administration in all animals and remained above that target for at least 288 h (12 days) on average. No negative effects were observed. The subcutaneous route of administration was preferred due to ease of administration. A single administration of CCFA at 30 mg/kg SC appears to be a safe long-acting antibiotic in bearded dragons.

Endnote

a. EXCEDE®, Zoetis, Madison, NJ, USA.

Acknowledgments

This project was supported by the University of Wisconsin - School of Veterinary Medicine’s Companion Animal Fund.

Literature Cited

1.  Adkesson M.J., E. Fernandez-Varon, S. Cox, and T. Martin-Jimenez. 2011. Pharmacokinetics of a long-acting ceftiofur formulation (ceftiofur crystalline free acid) in the ball python (Python regius). J. Zoo Wildl. Med. 42:444–450.

2.  Brown S.A., R. Yancy, and J. Stefan. 1991. Ceftiofur sodium: antimicrobial activity of parent ceftiofur and metabolites. Acta Vet. Scand. 87(suppl):95–97.

3.  Salmon S.A., and J. L. Watts. 2000. Minimum inhibitory concentration determinations for various antimicrobial agents against 1570 bacterial isolates from turkey poults. Avian Dis. 44:85-98.

 

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Sarah M. Churgin, DVM
Department of Surgical Sciences, Special Species Health Service
University of Wisconsin
Madison, WI, USA


MAIN : AAZV Conference : SQ vs. IM Ceftiofur in Inland Bearded Dragons
Powered By VIN
SAID=27